Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity

Clinical Cancer Research

Volumn 21, Issue 23, 2015, Pages 5380-5390

  Zhang, Ningyan ^a   Deng, Hui ^a   Fan, Xuejun ^a   Gonzalez, Anneliese ^a   Zhang, Songlin ^a   Brezski, Randall J ^b   Choi, Byung Kwon ^a   Rycyzyn, Michael ^b   Strohl, William ^b   Jordan, Robert ^a,b   An, Zhiqiang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GELATINASE B; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASE;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST TUMOR; DISEASE MODEL; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; LYMPH NODE METASTASIS; MACROPHAGE; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; PROTEIN DEGRADATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; LYMPHATIC METASTASIS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; NEOPLASMS; PROTEOLYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84954108394     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1057     Document Type: Article

References (46)

1. Lu H, Ladd J, Feng Z,WuM,Goodell V, Pitteri SJ, et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res 2012;5:1036-43.
2. Piura E, Piura B. Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol 2010;2010:264926.
3. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-3.
4. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011;331: 1565-70.
5. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science Transl Med 2012;4:127ra37.
6. Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: An evasion tactic against host immunity? mAbs 2010;2: 212-20.
7. Brezski RJ, KinderM, Grugan KD, Soring KL, Carton J, Greenplate AR, et al. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. mAbs 2014;6:1265-73.
8. Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, Ryan MH, et al. Tumorassociated andmicrobial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A 2009;106:17864-9.
9. Fan X, Brezski RJ, Deng H, Dhupkar P, Shi Y, Gonzalez A, et al. A novel therapeutic strategy to rescue the immune effector function of proteolytically-inactivated cancer therapeutic antibodies. Mol Cancer Ther 2015;14: 681-91.
10. Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, et al. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res 2012;14: R116.
11. Brezski RJ, Luongo JL, Petrone D, Ryan MH, Zhong D, Tam SH, et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol 2008;181:3183-92.
12. Kinder M, Greenplate AR, Grugan KD, Soring KL, Heeringa KA, McCarthy SG, et al. Engineered protease-resistant antibodies with selectable cellkilling functions. J Biol Chem 2013;288:30843-54.
13. Huang Z, Choi BK, Mujoo K, Fan X, Fa M, Mukherjee S, et al. The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling. Oncogene 2015;34:1105-15.
14. Ryan MH, Petrone D, Nemeth JF, Barnathan E, Bjorck L, Jordan RE. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 2008;45:1837-46.
15. Fa M, Hoch K, Fan X, Dubinsky W, An Z, Zhang N. Novel approach for quantitative measurement ofmatrix metalloprotease-1 (MMP1) in human breast cancer cells using mass spectrometry. J Anal Sci Method and Instrument (JASMI) 2013;3:54-61.
16. McCartyKS Jr, Szabo E, Flowers JL, Cox EB, LeightGS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986;46:4244s-8s.
17. Zhang N, Liu L, Dumitru CD, Cummings NR, Cukan M, Jiang Y, et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. mAbs 2011;3:289-98.
18. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34.
19. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008;29:57-61.
20. Vincents B, Guentsch A, Kostolowska D, von Pawel-Rammingen U, Eick S, Potempa J, et al. Cleavage of IgG1 and IgG3 by gingipain K from Porphyromonas gingivalis may compromise host defense in progressive periodontitis. FASEB J 2011;25:3741-50.
21. Vincents B, von Pawel-Rammingen U, Bjorck L, AbrahamsonM. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 2004;43:15540-9.
22. Jefferis R. Antibody therapeutics: Isotype and glycoform selection. Expert Opin Biol Ther 2007;7:1401-13.
23. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005;310:1510-2.
24. Gearing AJ, Thorpe SJ, Miller K, Mangan M, Varley PG, Dudgeon T, et al. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 2002;81:41-8.
25. Brezski RJ, Oberholtzer A, Strake B, Jordan RE. The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge. mAbs 2011;3: 558-67.
26. Grugan KD, McCabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, et al. Tumor-associated macrophages promote invasion while retaining Fcdependent anti-tumor function. J Immunol 2012;189:5457-66.
27. Yuan ZY, Luo RZ, Peng RJ, Wang SS, Xue C. High infiltration of tumorassociated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco Targets Ther 2014;7:1475-80.
28. van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002;2:251-2.
29. Dougan M, Dranoff G. The immune response to tumors. Curr Protoc Immunol 2009;Chapter 20:Unit 20 11.
30. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-67.
31. Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment ofmetastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children's oncology group. J Clin Oncol 2012;30:2545-51.
32. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007;19:239-45.
33. Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtypespecific breast and ovarian cancer. Clin Cancer Res 2014;20:3818-29.
34. Whiteside TL, Ferrone S. For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res 2012;18:2417-9.
35. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 2001;98:12659-64.
36. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2012;132:545-53.
37. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012;18:2695-703.
38. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: Their value as diagnostic and prognosticmarkers and therapeutic targets. Tumour Biol 2013;34:2041-51.
39. Bauvois B. New facets of matrix metalloproteinasesMMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012;1825:29-36.
40. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010;141:52-67.
41. Gingis-Velitski S, Loven D, Benayoun L, MunsterM, Bril R, Voloshin T, et al. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 2011;71:6986-96.
42. Puolakkainen P, Koski A, Vainionpaa S, Shen Z, Repo H, Kemppainen E, et al. Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Med Oncol 2014;31:884.
43. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014;25:846-59.
44. Weber M, Buttner-Herold M, Hyckel P, Moebius P, Distel L, Ries J, et al. Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages-An immunohistochemical analysis. J Craniomaxillofac Surg 2014;42:1087-94.
45. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-29.
46. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.